Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
68 Results for "
glycosphingolipid
" in MedChemExpress (MCE) Product Catalog:
Products (68)
68 Results for "glycosphingolipid" in MCE Product Catalog:
1
1 Cited Publications
Target:
Research Areas:
Acid Ceramidase-IN-1 is orally active and blood-brain barrier penetrant acid ceramidase (AC, ASAH-1) inhibitor (hAC IC50=0.166 μM). Acid Ceramidase-IN-1 reduces AC activity, accumulates ceramide species (Cer (d18:0/16:0), Cer (d18:1/16:0)), and decreases sphingosine levels. Acid Ceramidase-IN-1 can be used for the study of severe neurological lysosomal storage diseases (LSDs) such as Gaucher’s disease (GD) and Krabbe’s disease (KD) .
Cat. No.: HY-N10546
CAS No.: 37758-47-7
Category:
Target:
Cat. No.: HY-E70038
CAS No.: 2763216-34-6
Target:
Research Areas:
Endoglycoceramidase II (EGCase II) is an endo-β-glucosidase that releases intact glycans from ceramides in glycosphingolipids. Endoglycoceramidase II catalyzes the hydrolysis of β-glycosidic linkages between oligosaccharides and ceramides in various glycosphingolipids .
Research Areas:
Ganglioside GM2 is a human tumor antigen predominantly found in human tumor cells and fetal brain tissue. As a sialylated glycosphingolipid, Ganglioside GM2 is involved in processes such as cell signaling, adhesion, and motility. Ganglioside GM2 abnormal expression and accumulation are associated with tumors and neurodegenerative disorders. Ganglioside GM2 promotes tumor cell migration and invasion by directly binding to the integrin β1 receptor, activating the FAK/Src/Erk-MAPK signaling pathway, and inducing actin cytoskeleton remodeling .
Cat. No.: HY-164236
CAS No.: 119242-44-3
Target:
Research Areas:
C22 Glucosylceramide (d18:1/22:0) is a bioactive sphingolipid composed of a d18:1 sphingoid base and a 22:0 fatty acid chain. C22 Glucosylceramide (d18:1/22:0) specifically exists in Doxorubicin (HY-15142A)-sensitive cancer cells, and its circulating concentration is positively correlated with the incidence of cardiovascular events. C22 Glucosylceramide (d18:1/22:0) has been widely used in research related to cardiovascular diseases, hypercholesterolemia, metabolic syndrome, breast adenocarcinoma and other fields .
Cat. No.: HY-N0899
CAS No.: 11088-09-8
Cat. No.: HY-W341625
CAS No.: 474943-80-1
Target:
Research Areas:
Trihexosylceramide (d18:1/12:0) is a glycosphingolipid and mood-related compound. Trihexosylceramide (d18:1/12:0) is characterized by elevated serum levels in Mus musculus fed a high-fat diet, and its levels are positively correlated with mood Z-scores. Accumulation of Trihexosylceramide (d18:1/12:0) in tissues is considered the etiology of angiokeratoma corporis diffusum. Trihexosylceramide (d18:1/12:0) can be used in studies related to high-fat diet-induced mood disorders .\n
Cat. No.: HY-170035
CAS No.: 95119-86-1
Synonyms: C18 Glucosyl(β) ceramide (d18:1/18:0); D-glucosyl-β-1,1' N-stearoyl-D-erythro-sphingosine
GlcCer (d18:1/18:0) (C18 Glucosyl(β) ceramide (d18:1/18:0)) is a glycosphingolipids that activates the Wnt/β-catenin pathway by targeting LRP6. GlcCer (d18:1/18:0) drives EMT, migration, invasion and GBA1-mediated liver cancer metastasis. GlcCer (d18:1/18:0) accumulates to impair lysosomal function and induce toxic α-synuclein aggregation. GlcCer (d18:1/18:0) supports growth, sporulation, germination and virulence in Penicillium digitatum. GlcCer (d18:1/18:0) is reduced in demyelinated mouse corpus callosum. GlcCer (d18:1/18:0) can be used for the research of liver cancer, synucleinopathies, fungal, Parkinson’s disease and Gaucher disease .
Cat. No.: HY-W747597
CAS No.: 19553-76-5
Synonyms: Disialoganglioside GD1b; Ganglioside C1; Ganglioside G2
Target:
Research Areas:
Ganglioside GD1b Disodium Salt (Bovine Brain) (Disialoganglioside GD1b; Ganglioside C1) is an acidic glycosphingolipid containing two sialic acid residues linked to an internal galactose unit. Ganglioside GD1b Disodium Salt tightly packs with cholesterol to form lipid microdomains that modulate intracellular and intercellular signaling events. Concentrations of Ganglioside GD1b Disodium Salt (Bovine Brain) in the human brain increase with age and are positively correlated with pilocytic astrocytoma tumor grade. Ganglioside GD1b Disodium Salt has been detected in various other gliomas, including primitive neuroectodermal tumors, glioblastomas, and anaplastic astrocytomas.
Cat. No.: HY-116392E
CAS No.: 109836-82-0
Research Areas:
D-threo-PDMP is a potent glucoceramide synthase (GCS) inhibitor, which reduces the glycosphingolipids (such as GM3 and GD3) on the cell surface by inhibiting glycosylation, reduces the total length of the axon plexus and the number of axon branch points, and inhibits neurite growth. D-threo-PDMP inhibits the synthesis of GM3, thereby reducing the adhesion ability of B16 melanoma cells and mimicking the pathological effects of hyperglycemia/TGF-β1. D-threo-PDMP inhibits the synthesis of GD3, thereby protecting liver cells from apoptosis induced by TNF-α. D-threo-PDMP can be used to study diseases related to targeted glycosphingolipid metabolism .
Cat. No.: HY-50055
CAS No.: 245329-78-6
EtDO-P4 is a nanomolar inhibitor of glycosphingolipid (GSL) synthesis. EtDO-P4 suppresses activation of the EGFR-induced ERK pathway and various receptor tyrosine kinases (RTKs). EtDO-P4 can be used for various types of cancer, including Burkitt’s lymphoma .
Target:
Research Areas:
D-threo-PDMP hydrochloride is a potent glucoceramide synthase (GCS) inhibitor, which reduces the glycosphingolipids (such as GM3 and GD3) on the cell surface by inhibiting glycosylation, reduces the total length of the axon plexus and the number of axon branch points, and inhibits neurite growth. D-threo-PDMP hydrochloride inhibits the synthesis of GM3, thereby reducing the adhesion ability of B16 melanoma cells and mimicking the pathological effects of hyperglycemia/TGF-β1. D-threo-PDMP hydrochloride inhibits the synthesis of GD3, thereby protecting liver cells from apoptosis induced by TNF-α. D-threo-PDMP hydrochloride can be used to study diseases related to targeted glycosphingolipid metabolism .
Cat. No.: HY-E70047
CAS No.: 52725-57-2
Synonyms: A4GALT
Target:
Research Areas:
alpha-1,4-Galactosyltransferase (LgtC) (A4GALT) is a glycosphingolipid-specific glycosyltransferase. alpha-1,4-Galactosyltransferase (LgtC) transfers a galactose to the alpha-1,4 position of lactosylceramide to form globotriaosylceramide. alpha-1,4-Galactosyltransferase (LgtC) can be used for the synthesis of P1 blood group antigens .
Cat. No.: HY-156209
CAS No.: 137896-85-6
Target:
Research Areas:
Gb3 (d18:1/16:0) (Compound 1) is the P k antigen of the P blood group system. Gb3 (d18:1/16:0) acts as a cell surface receptor. Gb3 (d18:1/16:0) is used for research on Burkitt's lymphoma, teratocarcinoma, embryonal carcinoma, and Fabry's disease .
Cat. No.: HY-76981
CAS No.: 28315-93-7
Category:
Monophenols Ketones, Aldehydes, Acids Other Diseases Phenols Endogenous metabolite Disease Research Fields
Target:
Cat. No.: HY-N10546A
CAS No.: 1007119-81-4
Target:
Research Areas:
Ganglioside GM1 (bovine) ammonium is a type of glycosphingolipid, mainly found on the cell membranes of the central nervous system of vertebrates. Ganglioside GM1 (bovine) ammonium exerts neuroprotective effects by reducing excessive activation of NMDAR, activating TrkA and ERK1/2, and inhibiting oxidative stress and cell apoptosis and autophagy. Ganglioside GM1 (bovine) ammonium can be used in the research of diseases such as traumatic brain injury, Parkinson's disease, Alzheimer's disease, and Huntington's disease .
Cat. No.: HY-165035
CAS No.: 85305-87-9
Synonyms: Glucocerebrosides; Gaucher cerebroside; GluCers (gaucher's spleen)
Research Areas:
Glucosylceramide (Glucocerebrosides) (gaucher's spleen) is a glycosphingolipid and primary substrate of acid β-glycosidase, suppresses tyrosine phosphorylation of insulin receptor and IRS-1, disrupts insulin signaling cascade and triggers pancreatic β-cell dysfunction. Glucosylceramide (Gaucher's spleen) accumulates in rodents and induces obesity and insulin resistance, restores systemic glucose homeostasis and insulin sensitivity when synthesis is suppressed. Glucosylceramide (Gaucher's spleen) accumulates in the brain of chronic neuronopathic Gaucher disease mice with age and can be applied for research on insulin resistance, type 2 diabetes mellitus and chronic neuronopathic Gaucher disease .
Cat. No.: HY-N10526
CAS No.: 41744-59-6
Synonyms: Gala-3Galb-4Glc
Category:
Target:
Cat. No.: HY-E70282
Synonyms: rEGCase I assisted by activator II
Target:
Research Areas:
Recombinant endoglycoceramidase I assisted by activator II (rEGCase I assisted by Activator II) is a mixture-form of EGCase I and Activator II. EGCase I is a glycolipid-specific hydrolase that well-suited to a comprehensive analysis of glycosphingolipids (GSLs). Activator II is capable of inducing activity of EGCase without any detergent reagents .
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
